We observed that CD16+ monocytes from patients were able to lyse a significantly higher proportion of trastuzumab-coated SKBR3 cell lines and rituximab-coated primary B-CLL cells as compared to target cells not bound with antibodies (Fig. 7A,B; left panels striped bar respectively). This evidence concerns the gene FCGR3A and B-cell chronic lymphocytic leukemia.